FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation
Stock Information for FSD Pharma Inc.
Loading
Please wait while we load your information from QuoteMedia.